FRANKLIN, Tenn. / Dec 02, 2024 / Business Wire / Northwest Urgent Care, LLC, a Tucson, Arizona, subsidiary of Community Health Systems, Inc. (NYSE: CYH), has completed the acquisition of certain urgent care centers owned and operated by Carbon Health in Arizona.
Northwest Urgent Care, LLC is part of Northwest Healthcare’s integrated healthcare network serving Tucson and its surrounding communities. With this strategic acquisition, Northwest Healthcare now has more than 80 sites of care across the network.
Over the past five years, Northwest Healthcare has invested approximately $200 million in strategic growth and capital projects throughout the Greater Tucson Metro area, including two new hospitals – Northwest Medical Center Sahuarita and Northwest Medical Center Houghton. The Northwest Healthcare system provided medical care for more than 845,000 patient encounters in 2023.
About Community Health Systems, Inc.
Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 39 distinct markets across 15 states. The Company’s subsidiaries own or lease 70 affiliated hospitals with more than 11,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. More information about the Company can be found on its website at www.chs.net.
Last Trade: | US$3.27 |
Daily Change: | 0.06 1.87 |
Daily Volume: | 1,944,650 |
Market Cap: | US$454.370M |
December 11, 2024 September 16, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB